Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Autoimmune Disorders

  Free Subscription


24.06.2019

1 Am J Kidney Dis
1 Ann Neurol
1 BMC Neurol
1 Brain
6 Diabet Med
1 J Autoimmun
2 J Immunol
1 J Neurol
2 J Rheumatol
1 Lancet Neurol
6 Mult Scler
1 N Engl J Med
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Kidney Dis

  1. GALLAN AJ, Alexander E, Reid P, Kutuby F, et al
    Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
    Am J Kidney Dis. 2019 Jun 13. pii: S0272-6386(19)30736.
    PubMed     Text format     Abstract available


    Ann Neurol

  2. MUNGER KL, Hongell K, Cortese M, Aivo J, et al
    Epstein-Barr virus and multiple sclerosis risk in the Finnish Maternity Cohort.
    Ann Neurol. 2019 Jun 21. doi: 10.1002/ana.25532.
    PubMed     Text format     Abstract available


    BMC Neurol

  3. KOLB-MAURER A, Sunderkotter C, Kukowski B, Meuth SG, et al
    An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
    BMC Neurol. 2019;19:130.
    PubMed     Text format     Abstract available


    Brain

  4. FILIPPI M, Preziosa P, Banwell BL, Barkhof F, et al
    Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.
    Brain. 2019 Jun 17. pii: 5519813. doi: 10.1093.
    PubMed     Text format     Abstract available


    Diabet Med

  5. HIRST JA, Farmer AJ, Smith MC, Stevens RJ, et al
    Timings for HbA1c testing in people with diabetes are associated with incentive payments: an analysis of UK primary care data.
    Diabet Med. 2018 Sep 3. doi: 10.1111/dme.13810.
    PubMed     Text format     Abstract available

  6. EVANS-CHEUNG TC, Campbell F, Yong J, Parslow RC, et al
    HbA1c values and hospital admissions in children and adolescents receiving continuous subcutaneous insulin infusion therapy.
    Diabet Med. 2019;36:88-95.
    PubMed     Text format     Abstract available

  7. CHETAN MR, Charlton MH, Thompson C, Dias RP, et al
    The Type 1 diabetes 'honeymoon' period is five times longer in men who exercise: a case-control study.
    Diabet Med. 2018 Aug 17. doi: 10.1111/dme.13802.
    PubMed     Text format     Abstract available

  8. FREDRIX M, Byrne M, Dinneen S, McSharry J, et al
    'It's an important part, but I am not quite sure that it is working': educators' perspectives on the implementation of goal-setting within the 'DAFNE' diabetes structured education programme.
    Diabet Med. 2018 Sep 3. doi: 10.1111/dme.13813.
    PubMed     Text format     Abstract available

  9. PANG T, Bain SC, Black RNA, Boyle JG, et al
    A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).
    Diabet Med. 2018 Oct 25. doi: 10.1111/dme.13847.
    PubMed     Text format     Abstract available

  10. HENRIKSEN MM, Andersen HU, Thorsteinsson B, Pedersen-Bjergaard U, et al
    Asymptomatic hypoglycaemia in Type 1 diabetes: incidence and risk factors.
    Diabet Med. 2018 Oct 27. doi: 10.1111/dme.13848.
    PubMed     Text format     Abstract available


    J Autoimmun

  11. TSAI HC, Nguyen K, Hashemi E, Engleman E, et al
    Myeloid sphingosine-1-phosphate receptor 1 is important for CNS autoimmunity and neuroinflammation.
    J Autoimmun. 2019 Jun 12. pii: S0896-8411(19)30209.
    PubMed     Text format     Abstract available


    J Immunol

  12. FELTON JL, Maseda D, Bonami RH, Hulbert C, et al
    Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes.
    J Immunol. 2018 Jun 27. pii: jimmunol.1701717. doi: 10.4049/jimmunol.1701717.
    PubMed     Text format     Abstract available

  13. VASQUEZ M, Consuegra-Fernandez M, Aranda F, Jimenez A, et al
    Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-alpha.
    J Immunol. 2019 Jun 17. pii: jimmunol.1801462. doi: 10.4049/jimmunol.1801462.
    PubMed     Text format     Abstract available


    J Neurol

  14. FRAU J, Sacca F, Signori A, Baroncini D, et al
    Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    J Neurol. 2019 Jun 17. pii: 10.1007/s00415-019-09424.
    PubMed     Text format     Abstract available


    J Rheumatol

  15. WONG PC, Lee G, Sedie AD, Hanova P, et al
    Musculoskeletal Ultrasound in Systemic Lupus Erythematosus: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group.
    J Rheumatol. 2019 Jun 15. pii: jrheum.181087. doi: 10.3899/jrheum.181087.
    PubMed     Text format     Abstract available

  16. STOJAN G, Magder LS, Petri M
    Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus.
    J Rheumatol. 2019 Jun 15. pii: jrheum.181131. doi: 10.3899/jrheum.181131.
    PubMed     Text format     Abstract available


    Lancet Neurol

  17. FEINSTEIN A
    Wordsworth, Bellow, and understanding multiple sclerosis.
    Lancet Neurol. 2019 Jun 14. pii: S1474-4422(19)30222.
    PubMed     Text format    


    Mult Scler

  18. CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
    Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
    Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
    PubMed     Text format     Abstract available

  19. CHATAWAY J, Weir CJ, Fox RJ
    The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
    Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
    PubMed     Text format    

  20. FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
    Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
    Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
    PubMed     Text format     Abstract available

  21. MARCK CH, das Nair R, Grech LB, Borland R, et al
    Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
    Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
    PubMed     Text format     Abstract available

  22. PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
    A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
    Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
    PubMed     Text format     Abstract available

  23. CHARD DT
    Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
    Mult Scler. 2019;25:298-299.
    PubMed     Text format     Abstract available


    N Engl J Med

  24. BRAUN DA, Henderson GV, Sax PE, Miller AL, et al
    A Disturbing Decline.
    N Engl J Med. 2019;380:2257-2262.
    PubMed     Text format    


    Proc Natl Acad Sci U S A

  25. KREMER D, Gruchot J, Weyers V, Oldemeier L, et al
    pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.
    Proc Natl Acad Sci U S A. 2019 Jun 18. pii: 1901283116.
    PubMed     Text format     Abstract available


  26. Correction for McKenzie et al., Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis.
    Proc Natl Acad Sci U S A. 2019 Jun 17. pii: 1909025116.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: